Dementia etiology classification using NULISA plasma biomarkers and machine learning
DuBois, K. N.; Pal, S.; Cook Maher, A.; Heidebrink, J.; Persad, C.; Giordani, B. M.; Hampstead, B. M.; Bakulski, K. M.; Morgan, D. G.; Kanaan, N. M.
Show abstract
INTRODUCTIONAccurate antemortem differentiation among dementia etiologies remains challenging, particularly for atypical or mixed clinical presentations. Multiplexed plasma proteomics paired with supervised machine-learning offers a minimally invasive and accessible approach for differential diagnosis. METHODSPlasma from 194 participants was analyzed using the NULISA CNS 120+ plasma biomarker panel. Differentially abundant protein patterns associated with AD, frontotemporal lobar degeneration, Lewy body disease, and vascular disease were identified. These features were used to train supervised XGBoost classifier models. Models were then applied to participants with mild cognitive impairment to generate data-driven predictions of etiology. RESULTSNULISA plasma biomarkers revealed disease-specific protein patterns. XGBoost classifiers differentiated disease etiologies with high specificity. Application of the models to participants with mild cognitive impairment yielded robust etiologic predictions. DISCUSSIONThese results support the feasibility of using multiplexed NULISA plasma proteomics, combined with machine learning, for differential diagnosis of complex neurodegenerative dementia etiologies. HighlightsO_LIMultiplex plasma proteomics revealed distinct protein markers of dementia subtypes C_LIO_LISupervised XGBoost classifiers accurately distinguished each dementia etiology C_LIO_LIModel application to unknown etiologies produced interpretable probability profiles C_LIO_LIThe combined NULISA-machine learning framework demonstrates diagnostic feasibility C_LI Research in ContextO_LISystematic review: The authors reviewed the literature using traditional sources (e.g. PubMed), meeting abstracts and presentations. NULISA technology has been utilized to analyze blood biomarkers in people with neurological diseases and differential protein expression based on clinical diagnosis and presumed etiologies has been observed. These citations are appropriately cited. C_LIO_LIInterpretation: Our findings indicate that machine learning can be used in combination with NULISA technology to improve etiology prediction in people with dementia. C_LIO_LIFuture directions: Future studies using larger, more well-balanced participant cohorts will enable better understanding of the plasma biomarkers and demographic factors that best discriminate between dementia etiologies. C_LI
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
- Plasma p-tau181/Aβ 1-42 ratio predicts Aβ-PET status and correlates with CSF-p-tau181/Aβ 1-42 and future cognitive decline 97%
- CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status 97%
- Plasma p217+tau vs NAV4694 amyloid and MK6240 tau PET across the Alzheimer continuum 96%
Similar papers in this journal
- A conformational variant of p53 (U-p53 AZ ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease 97%
- Identifying Proteomic Prognostic Markers for Alzheimer’s Disease with Survival Machine Learning: the Framingham Heart Study 96%
- Continuous Associations Between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer’s Disease 95%
Similar papers in this journal
Similar papers in this journal
- CSF sphingomyelins in Alzheimer’s disease, neurodegeneration, and neuroinflammation 97%
- Liver-specific polygenic risk score is more strongly associated than genome-wide score with Alzheimer’s disease diagnosis in a case-control analysis 97%
- Inferring Alzheimer’s disease pathologic traits from clinical measures in living adults 97%